Agency Information Collection Activities: Proposed Collection; Comment Request, 18307-18308 [2017-07764]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
Translational Sciences (NCATS) and the
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK).
Submissions may be sent
electronically to DK-IDG-Phase2-RFI@
mail.nih.gov or by mail to Dr. Karlie
Sharma, National Center for Advancing
Translational Sciences, National
Institutes of Health, 6701 Democracy
Blvd., Suite 900, Bethesda, MD 20892.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Questions about this request for
information should be directed to Dr.
Karlie Sharma, National Center for
Advancing Translational Sciences,
National Institutes of Health, 6701
Democracy Blvd., Suite 900, Bethesda,
MD 20892, DK-IDG-Phase2-RFI@
mail.nih.gov, 301–451–4965.
Out of the
nearly 30,000 genes in the human
genome, approximately 3,000 genes are
estimated to be part of the druggable
genome—the subset of genes expressing
proteins with the ability to bind druglike molecules. Yet, only about ten
percent of druggable proteins are
targeted by Food and Drug
Administration (FDA)-approved drugs.
Many proteins that comprise the
druggable genome are members of the Gprotein coupled receptor (GPCR), ion
channel, and kinase families. A
significant number of proteins within
these classes are understudied and are
the focus of the data and resource
generation initiative of the IDG Program.
SUPPLEMENTARY INFORMATION:
sradovich on DSK3GMQ082PROD with NOTICES
1. Goals and Requirements
The IDG Program was originally
funded as a three-year pilot program in
2014 with two overarching goals: (1)
Integrate information about
understudied druggable proteins from
disparate sources into a single
informatics site and (2) foster
technology development to enable the
determination of function and
therapeutic potential of understudied
druggable proteins. Having successfully
achieved these goals, the IDG Program is
currently transitioning to a new
implementation phase intended to:
• Expand the informatics tools
developed in the pilot phase to include
additional data and allow users to
access, analyze, and visualize a wide
range of information on sets of proteins.
• Facilitate the elucidation of the
function of understudied proteins from
the three key druggable protein families
(GPCR, ion channels, and kinases) by
generating new reagents and new data.
• Disseminate the IDG-generated
resources and data to the greater
scientific community.
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
2. Information Requested
NIH is seeking input from national
and international experts and interested
members of the public that includes, but
is not limited to, the following areas:
• Resources that an outside
organization (biotechnology or
pharmaceutical company; non-profit
organization; academic institution and
national/international consortia) might
be willing to share with the IDG
Program and may:
Æ Strategize development of chemical
probes against proteins drawn from
the IDG focused list
Æ develop assays and platforms that can
help to answer questions about
understudied protein function
Æ identify reagents that may be useful
in annotation efforts
Æ provide data or knowledge on any
understudied protein
• Potential resources of the IDG
Program that are of interest to an outside
organization of the broader biomedical
research community including:
Æ Sharable databases of relevant subsets
of data on understudied proteins
Æ data analysis and query tools
Æ links between protein target and
disease pathologies
Æ new methods of analysis to accelerate
collection of data
This RFI is for planning purposes
only and should not be construed as a
solicitation for applications or
proposals, or as an obligation in any
way on the part of the United States
Federal government. The Federal
government will not pay for the
preparation of any information
submitted or for the government’s use.
Additionally, the government cannot
guarantee the confidentiality of the
information provided.
Dated: April 12, 2017.
Christopher P. Austin,
Director, NCATS.
Griffin P. Rodgers,
Director, NIDDK, Illuminating the Druggable
Genome Program, National Center for
Advancing Translational Sciences, National
Institute of Diabetes and Digestive and Kidney
Diseases.
[FR Doc. 2017–07795 Filed 4–17–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
18307
DEPARTMENT OF HEALTH AND
HUMAN SERVCES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed project or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer at (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Proposed Project: Strategic Prevention
Framework for Prescription Drugs
(SPF-Rx)—New
The Substance Abuse and Mental
Health Services Administration
(SAMHSA)’s Center for Substance
Abuse Prevention (CSAP) aims to
conduct a cross-site evaluation of the
Strategic Prevention Framework for
Prescription Drugs (SPF-Rx) program.
The SPF-Rx program is designed to
address nonmedical use of prescription
drugs (as well as opioid overdoses) by
raising awareness about the dangers of
sharing medications. and by working
with pharmaceutical and medical
communities. The SPF-Rx program aims
to promote collaboration between states/
tribes and pharmaceutical and medical
communities to understand the risks of
overprescribing to youth ages 12–17 and
adults 18 years of age and older. The
program also aims to enhance capacity
for, and access to, Prescription Drug
Monitoring Program (PDMP) data for
prevention purposes.
The SPF-Rx program aims to address
SAMHSA’s priorities on prevention and
E:\FR\FM\18APN1.SGM
18APN1
18308
Federal Register / Vol. 82, No. 73 / Tuesday, April 18, 2017 / Notices
reduction of prescription drug and illicit
opioid misuse and abuse. Its indicators
of success are reductions in opioid
overdoses and the incorporation of
PDMP data into needs assessments and
strategic plans. Data collected through
the tools described in this statement
will be used for the national cross-site
evaluation of SAMHSA’s SPF-Rx
program. This package covers continued
data collection through 2020, as the
evaluation is expected to continue
through at least that time; however, the
Program Evaluation for Prevention
Contract (PEP–C) is scheduled to
conduct a national cross-site evaluation
of SPF-Rx through September 2018. The
PEP–C team will systematically collect
and maintain an Annual
Implementation Instrument (AII) and
outcomes data submitted by SPF-Rx
grantees through the online PEP–C
Management Reporting Tool (MRT).
SAMHSA is requesting approval for
data collection for the SPF-Rx cross-site
evaluation with the following four
instruments:
• Substitute Data Source Request to
allow grantees to request permission
from SAMHSA to use ‘‘substitute
measures’’ for their outcomes data—that
is, measures that differ from a list of
preapproved outcomes measures.
• Annual Implementation Instrument
to collect data completed by grantees
and subrecipient community PDs. Data
collected from the survey will be used
to monitor subrecipient and state, tribal
entity, or jurisdiction performance, and
to evaluate the effectiveness of the SPFRx program across states, tribal entities,
and jurisdictions.
• Grantee Interview to collect
semistructured telephone interview data
to gather more in-depth information on
organizational infrastructure, use of
PDMP data.
• Evaluation Plan to allow grantees to
outline their local evaluation plan. This
section should include goals and
objectives, performance measures, a
data analysis plan, and reporting plan.
• Grantee Interview to obtain the
perspective of the implementing Project
Directors (PDs) or their staff on
important topics, including
infrastructure and capacity,
collaboration, leveraging funding and
resources, criteria and use of evidenceinformed interventions, monitoring and
evaluation, collaboration, challenges,
and health disparities. Information from
these interviews will help inform SPFRx cross-site evaluation reports and will
help identify lessons learned and
success stories from grantees’ SPF-Rx
programs.
• Grantee- and Community-Level
Outcomes Modules to collect data on
key SPF-Rx program outcomes,
including opioid misuse and abuse,
opioid overdoses, and opioid
prescribing patterns. Grantees will
provide outcomes data at the grantee
level for their state, tribal area, or
jurisdiction, as well as at the
community level for each of their
subrecipient communities.
ANNUALIZED DATA COLLECTION BURDEN
Number of
respondents
Instrument
Grantee-Level Outcomes Module ........................................
Community-Level Outcomes Module ...................................
Substitute Data Request Form ............................................
Annual Implementation Instrument ......................................
Grantee-Level Interview .......................................................
Evaluation Plan ....................................................................
Overall Total .................................................................
25
25
3.67
100
17
25
170.67
Responses
per
respondent
Total number
of responses
1
1
1
1
1
1
........................
25
25
3.67
100
17
25
170.67
Hours per
response
3
3
1
2.3
1.5
8
........................
Total burden
hours
75
75
3.67
230
25.5
200
609.17
Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost
over the 3 years (FY2018–FY2020).
Send comments to Summer King,
SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57–B,
Rockville, Maryland 20857, OR email a
copy to summer.king@samhsa.hhs.gov.
Written comments should be received
by June 19, 2017.
Summer King,
Statistician.
[FR Doc. 2017–07764 Filed 4–17–17; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF THE INTERIOR
Bureau of Land Management
[LLCAN01000 L10200000.XZ0000 17X
LXSIOVHD0000]
Notice of Public Meeting: Northern
California District Resource Advisory
Council
Bureau of Land Management,
Interior.
ACTION: Notice.
AGENCY:
In accordance with the
Federal Land Policy and Management
Act of 1976, and the Federal Advisory
Committee Act of 1972, the U.S.
Department of the Interior, Bureau of
Land Management’s (BLM) Northern
California District Resource Advisory
Council (RAC) will meet as indicated
below.
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
The meeting will be held on
Wednesday, April 26, 2017, from 10
DATES:
VerDate Sep<11>2014
16:55 Apr 17, 2017
Jkt 241001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
a.m. to 4 p.m. The meeting is open to
the public. Public comments will be
accepted at 11 a.m. to noon.
ADDRESSES: The meeting will be held in
the conference room of the Bureau of
Land Management Northern California
District Office, 6640 Lockheed Drive,
Redding, CA 96002. Those unable to
attend can participate by teleconference.
The toll-free telephone number is (888)
282–0374, and the passcode is 50716.
Written comments can be sent to the
district office at the above address.
FOR FURTHER INFORMATION CONTACT:
BLM Northern California District
Manager, Alan Bittner, (530) 224–2160;
or Public Affairs Officer, Joseph J.
Fontana, (530) 252–5332. Persons who
use a telecommunications device for the
deaf may call the Federal Relay Service
at 800–877–8339, to contact the above
individuals during normal business
hours. The Service is available 24 hours
a day, 7 days a week, to leave a message
or question with the above individual.
E:\FR\FM\18APN1.SGM
18APN1
]]>Agencies
[Federal Register Volume 82, Number 73 (Tuesday, April 18, 2017)]
[Notices]
[Pages 18307-18308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07764]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVCES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed project
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer at (240) 276-1243.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Strategic Prevention Framework for Prescription Drugs
(SPF-Rx)--New
The Substance Abuse and Mental Health Services Administration
(SAMHSA)'s Center for Substance Abuse Prevention (CSAP) aims to conduct
a cross-site evaluation of the Strategic Prevention Framework for
Prescription Drugs (SPF-Rx) program. The SPF-Rx program is designed to
address nonmedical use of prescription drugs (as well as opioid
overdoses) by raising awareness about the dangers of sharing
medications. and by working with pharmaceutical and medical
communities. The SPF-Rx program aims to promote collaboration between
states/tribes and pharmaceutical and medical communities to understand
the risks of overprescribing to youth ages 12-17 and adults 18 years of
age and older. The program also aims to enhance capacity for, and
access to, Prescription Drug Monitoring Program (PDMP) data for
prevention purposes.
The SPF-Rx program aims to address SAMHSA's priorities on
prevention and
[[Page 18308]]
reduction of prescription drug and illicit opioid misuse and abuse. Its
indicators of success are reductions in opioid overdoses and the
incorporation of PDMP data into needs assessments and strategic plans.
Data collected through the tools described in this statement will be
used for the national cross-site evaluation of SAMHSA's SPF-Rx program.
This package covers continued data collection through 2020, as the
evaluation is expected to continue through at least that time; however,
the Program Evaluation for Prevention Contract (PEP-C) is scheduled to
conduct a national cross-site evaluation of SPF-Rx through September
2018. The PEP-C team will systematically collect and maintain an Annual
Implementation Instrument (AII) and outcomes data submitted by SPF-Rx
grantees through the online PEP-C Management Reporting Tool (MRT).
SAMHSA is requesting approval for data collection for the SPF-Rx
cross-site evaluation with the following four instruments:
Grantee Interview to obtain the perspective of the
implementing Project Directors (PDs) or their staff on important
topics, including infrastructure and capacity, collaboration,
leveraging funding and resources, criteria and use of evidence-informed
interventions, monitoring and evaluation, collaboration, challenges,
and health disparities. Information from these interviews will help
inform SPF-Rx cross-site evaluation reports and will help identify
lessons learned and success stories from grantees' SPF-Rx programs.
Grantee- and Community-Level Outcomes Modules to collect
data on key SPF-Rx program outcomes, including opioid misuse and abuse,
opioid overdoses, and opioid prescribing patterns. Grantees will
provide outcomes data at the grantee level for their state, tribal
area, or jurisdiction, as well as at the community level for each of
their subrecipient communities.
Substitute Data Source Request to allow grantees to
request permission from SAMHSA to use ``substitute measures'' for their
outcomes data--that is, measures that differ from a list of preapproved
outcomes measures.
Annual Implementation Instrument to collect data completed
by grantees and subrecipient community PDs. Data collected from the
survey will be used to monitor subrecipient and state, tribal entity,
or jurisdiction performance, and to evaluate the effectiveness of the
SPF-Rx program across states, tribal entities, and jurisdictions.
Grantee Interview to collect semistructured telephone
interview data to gather more in-depth information on organizational
infrastructure, use of PDMP data.
Evaluation Plan to allow grantees to outline their local
evaluation plan. This section should include goals and objectives,
performance measures, a data analysis plan, and reporting plan.
Annualized Data Collection Burden
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Grantee-Level Outcomes Module... 25 1 25 3 75
Community-Level Outcomes Module. 25 1 25 3 75
Substitute Data Request Form.... 3.67 1 3.67 1 3.67
Annual Implementation Instrument 100 1 100 2.3 230
Grantee-Level Interview......... 17 1 17 1.5 25.5
Evaluation Plan................. 25 1 25 8 200
Overall Total............... 170.67 .............. 170.67 .............. 609.17
----------------------------------------------------------------------------------------------------------------
Note: Annualized Data Collection Burden captures the average number of respondents and responses, burden hours,
and respondent cost over the 3 years (FY2018-FY2020).
Send comments to Summer King, SAMHSA Reports Clearance Officer,
5600 Fishers Lane, Room 15E57-B, Rockville, Maryland 20857, OR email a
copy to summer.king@samhsa.hhs.gov. Written comments should be received
by June 19, 2017.
Summer King,
Statistician.
[FR Doc. 2017-07764 Filed 4-17-17; 8:45 am]
BILLING CODE 4162-20-P
